Antiviral interferons provide critical host defense mechanisms against viral infection. In the absence of IFN signaling, the host may be susceptible to lethal viral infection. IFNs protect host cells from viral disease by transcriptionally inducing hundreds of interferon-stimulated genes, which encode a variety of direct antiviral effectors and modulators of host defense signaling pathways. Our recent screening efforts have sought to identify novel human antiviral ISGs, characterize their mechanisms of action, and determine their specificity across a broad range of highly diverse viruses. The viruses of interest include several pathogens that are emerging or re-emerging infectious disease threats. Many of these viruses are transmitted to humans from natural animal reservoirs. Among the numerous reservoir hosts, bats are particularly unique in their ability to harbor highly pathogenic viruses with little to no overt disease. The mechanistic basis for the resistance of bats to viral disease s currently unknown, but several lines of evidence point to a potentially unique innate immune system. The goals of this project are to institute a bat ISG discovery pipeline, with an emphasis on the identification and characterization of novel antiviral mechanisms. Experimentally, we will synthesize a targeted bat ISG library using available bat genomic data. In parallel, we will establish methods for antiviral ISG enrichment from IFN-treated bat cells. Our previous cell-based flow cytometry screening platform will be miniaturized for rapid testing of bat ISGs against numerous viruses in a variety of bat and human cell lines. Follow-up mechanistic studies include the use of molecular virological tools to determine ISG modes of action in the viral life cycle, in addition to biochemical, genetic, and cell biological approaches to uncover th host-based mechanisms of antiviral action.

Public Health Relevance

Viruses continue to cause significant morbidity and mortality worldwide, with emerging viral diseases threatening large percentages of the world's population. Antiviral therapeutics are lacking for most of these viruses. We envision that bats may be a rich resource of naturally occurring antiviral molecules whose mechanisms may be harnessed for the development of novel therapeutics.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH Director’s New Innovator Awards (DP2)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Cassetti, Cristina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Schools of Medicine
United States
Zip Code
Mar, Katrina B; Rinkenberger, Nicholas R; Boys, Ian N et al. (2018) LY6E mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step. Nat Commun 9:3603
Rinkenberger, Nicholas; Schoggins, John W (2018) Mucolipin-2 Cation Channel Increases Trafficking Efficiency of Endocytosed Viruses. MBio 9:
De La Cruz-Rivera, Pamela C; Kanchwala, Mohammed; Liang, Hanquan et al. (2018) The IFN Response in Bats Displays Distinctive IFN-Stimulated Gene Expression Kinetics with Atypical RNASEL Induction. J Immunol 200:209-217
Richardson, R Blake; Ohlson, Maikke B; Eitson, Jennifer L et al. (2018) A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication. Nat Microbiol 3:1214-1223
Lipovsky, Alex; Erden, Asu; Kanaya, Eriko et al. (2017) The cellular endosomal protein stannin inhibits intracellular trafficking of human papillomavirus during virus entry. J Gen Virol 98:2821-2836
Perelman, Sofya S; Abrams, Michael E; Eitson, Jennifer L et al. (2016) Cell-Based Screen Identifies Human Interferon-Stimulated Regulators of Listeria monocytogenes Infection. PLoS Pathog 12:e1006102
Hanners, Natasha W; Eitson, Jennifer L; Usui, Noriyoshi et al. (2016) Western Zika Virus in Human Fetal Neural Progenitors Persists Long Term with Partial Cytopathic and Limited Immunogenic Effects. Cell Rep 15:2315-22